Exact Sciences Corp (NAS:EXAS)
$ 52.58 -0.94 (-1.76%) Market Cap: 9.70 Bil Enterprise Value: 11.61 Bil PE Ratio: 0 PB Ratio: 3.09 GF Score: 78/100

Exact Sciences Corp at Cowen HealthCare Conference Transcript

Mar 02, 2020 / 06:30PM GMT
Release Date Price: $77.43 (-4.35%)
Doug Schenkel
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

All right. Good afternoon. It's our pleasure to welcome Jeff Elliott and Megan Jones from Exact Sciences to the 40th Annual Cowen Health Care Conference. Exact Sciences is our tough larger cap growth pick for 2020. The company's Cologuard test is targeting an annual revenue opportunity of $17 billion.

There's a promising pipeline and the recent acquisition of Genomic Health, as not just the market-leading Oncotype test for predicting chemo benefit in breast cancer patients, but a platform for global growth and precision oncology, both organically and inorganically.

So Jeff, thanks for being here. We have a pretty aggressive list of topics to cover over the next 29 minutes. So thanks for being here. And now we'll get into that.

Jeffrey T. Elliott
Exact Sciences Corporation - CFO

I think that's it.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot